© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

France Bars Use Of Hydroxychloroquine In COVID-19 Cases

The move comes after the World Health Organization halted clinical trials of the drug as a treatment, citing a study that found no benefit and a higher mortality rate for hospitalized patients. A box of hydroxychloroquine, under the brand name Plaquenil, is seen in a pharmacy in Paris.
Chesnot
/
Getty Images
The move comes after the World Health Organization halted clinical trials of the drug as a treatment, citing a study that found no benefit and a higher mortality rate for hospitalized patients. A box of hydroxychloroquine, under the brand name Plaquenil, is seen in a pharmacy in Paris.

The French government is revoking a decree that had allowed hospitals to prescribe hydroxychloroquine in some COVID-19 cases, saying there is no proof that it helps patients — and citing data that shows it could cause heart problems and other health risks.

"This molecule must not be prescribed for patients affected by COVID-19," the Ministry of Solidarity and Health said as it announced the change.

The move to bar hospitals from prescribing the drug for coronavirus patients comes two days after the World Health Organization halted clinical trials of hydroxychloroquine as a treatment for COVID-19. The WHO cited a study published in The Lancet, that had found no benefit from the drug and reported a higher mortality rate for hospitalized patients and "an increased frequency of ventricular arrhythmias."

France's health ministry had approved hydroxychloroquine for emergency prescriptions in COVID-19 cases in late March.

As France 24 reports, that's when French researcher Didier Raoult, who has been an insistent proponent of hydroxychloroquine, said he had successfully treated COVID-19 patients using the controversial drug in combination with azithromycin. But the health ministry says recent studies show the treatment can produce "cardiac toxicity, particularly in combination with azithromycin."

Researchers continue to evaluate the possible use of hydroxychloroquine, which is used to treat malaria and lupus, to fight the coronavirus, with at least two studies underway in the U.S. As NPR's Joe Palca reports, the drug has been found to be able to prevent replication of the coronavirus.

President Trump has frequently touted hydroxychloroquine as a treatment for COVID-19 — and last week, he said that he was taking doses of both hydroxychloroquine and zinc to protect against the coronavirus, despite warnings about the drug.

"I've taken it for about a week and a half now. And I'm still here," he said.

Both the Food and Drug Administration and the National Institutes of Health have warned of health risks involved with people taking hydroxychloroquine hoping to prevent or treat COVID-19.

On the same day Trump said he was taking the drug, the FDA issued a list of its potentially dangerous side effects:

"Side effects of hydroxychloroquine include irreversible retinal damage, cardiac effects (including cardiomyopathy and QT prolongation), worsening of psoriasis and porphyria, proximal myopathy and neuropathy, neuropsychiatric events, and hypoglycemia."

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Bill Chappell is a writer and editor on the News Desk in the heart of NPR's newsroom in Washington, D.C.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content